hPD-1 Mice

The mouse Pdcd1 gene was edited using gene editing technology to replace the sequence encoding the extracellular domain of mouse PD-1 protein (aa.25~169) with the sequence from the human PD1 gene encoding the human PD-1 protein extracellular domain (aa.24~170) while retaining the mouse signal peptide.

Figure 1. Schematic representation of the gene editing strategy for generating hPD-1 mice.

1. Detection of Human PD1 Protein Expression in the Spleen

Figure 2. Detection of human PD1 (hCD279) expression after ex vivo activation of splenic cells. The results show that there is significant expression of human PD1 protein in the splenic cells of hPD1 mice 72 hours post-activation.

 

2. In vivo efficacy of anti-human PD-1 antibody

Figure 3. Evaluation of the Antitumor Activity of the Anti-human PD-1 Antibody in hPD-1 Mice. The colon adenocarcinoma model was established in female hPD1 mice (6 weeks old, n=5) via subcutaneous injection of the MC38 cells. Mice in the treatment group received the anti-human PD-1 antibody, Pembrolizumab, biweekly (BIW) ^[4]. During the experimental period, measurements of tumor volume and mouse weight were taken twice weekly, and at the end of the experiment, the mouse tumor tissue was removed for tumor weight measurement. The results showed that MC38 cells can form tumors in hPD-1 mice, and Pembrolizumab treatment can effectively inhibit tumor growth (Figure 3.a-b). While all mice exhibited a progressive increase in weight, a notable weight discrepancy was observed between the treatment and non-treatment groups (Figure 3.c).